Asian Pacific Journal of Cancer Biology (Apr 2023)
Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
- Mohamed Amine Bekadja,
- Pierre Fenaux,
- Sabrina Akrouf,
- Redhouane Ahmed-Nacer,
- Rose-marie Hamladji,
- Amina Bouchakour,
- Souad Taoussi,
- Mohand Tahar Abad,
- Mohamed Bradai,
- Brahim Benzineb,
- Naima Mesli,
- M Cheritti,
- Z Zouaoui,
- Mohamed Benlazar,
- Soraya Bougherira,
- Fatiha Grifi,
- Hocine Ait-Ali,
- Malika allouda,
- Malika Djillali,
- Khadija Djouadi,
- Fatima Kherbache,
- Selma Hamdi,
- Hakim Hamouda,
- Imene Boumeida,
- Meriem Belhani,
- Nadia Boudjerra,
- Fatima Zohra Kaci,
- Soufi Osmani,
- Nabil Yafour,
- Soumia Barkat,
- Fatma Soltani,
- Razika Nacib,
- Mahdia Saidi,
- Laid Touati,
- Noureddine Lakhdari,
- Samira Zouani,
- Hadj Touhami,
- Djamel Saidi,
- Lamia Cherif Louazani,
- Mohamed Ramaoun,
- Cherifa Akkal,
- Nemra Mehalhal,
- Amina Krim,
- Noureddine Sidimansour,
- Zohra Ouchenane,
- Nadia Zidani,
- Salim Nekkal,
- Samia Barkat,
- Y Ouarlent,
- Mohamed Aberkane,
- Salah Eddine Belakehal,
- Aissa Bachiri,
- Samir Baghdad
Affiliations
- Mohamed Amine Bekadja
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Pierre Fenaux
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Sabrina Akrouf
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Redhouane Ahmed-Nacer
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Rose-marie Hamladji
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Amina Bouchakour
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Souad Taoussi
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Mohand Tahar Abad
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Mohamed Bradai
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Brahim Benzineb
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Naima Mesli
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- M Cheritti
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Z Zouaoui
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Mohamed Benlazar
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Soraya Bougherira
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Fatiha Grifi
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Hocine Ait-Ali
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Malika allouda
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Malika Djillali
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Khadija Djouadi
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Fatima Kherbache
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Selma Hamdi
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Hakim Hamouda
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Imene Boumeida
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Meriem Belhani
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Nadia Boudjerra
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Fatima Zohra Kaci
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Soufi Osmani
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Nabil Yafour
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Soumia Barkat
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Fatma Soltani
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Razika Nacib
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Mahdia Saidi
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Laid Touati
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Noureddine Lakhdari
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Samira Zouani
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Hadj Touhami
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Djamel Saidi
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Lamia Cherif Louazani
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Mohamed Ramaoun
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Cherifa Akkal
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Nemra Mehalhal
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Amina Krim
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Noureddine Sidimansour
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Zohra Ouchenane
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Nadia Zidani
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Salim Nekkal
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Samia Barkat
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Y Ouarlent
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Mohamed Aberkane
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Salah Eddine Belakehal
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Aissa Bachiri
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- Samir Baghdad
- Hematology and Cell Therapy Department Ehu Oran, Algeria.
- DOI
- https://doi.org/10.31557/apjcb.2023.8.1.21-29
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 21 – 29
Abstract
Introduction: Myelodysplastic syndromes (MDS) are a group of haematological disorders, whose diagnosis is based mainly on cytological studies of blood and marrow cells and cytogenetic analysis. Moreover, national epidemiological data on MDS are very scarce, especially in Maghreb countries where the population is on average younger than in Europe or the USA. The objective of the present study was to describe demographic and clinical features and the overall survival of patients with MDS in Algeria. Materials and Methods: This study is retrospective and national multicenter (n=19 centres), performed between 2014 to 2019. The evaluation was performed using EPI-INFO and SPSS version 21 software. Survival data were calculated using the Kaplan-Meier method and comparison of survival curves using the Log Rank test. Univariate and multivariate analysis of survival was performed using the Cox regression method. The study has been approved by the Ethical and Scientific Council of the participating hospitals. The closing date of the study is 31/12/2019. Results: A total of 670 patients with newly diagnosed MDS have been identified. The average number of new cases was 112/year, with an annual progression rate of 19%. Demographics show a slight female predominance (M/F of 317/353=0, 89; sex ratio F/M=1.11). The median follow-up was 29,3 months (range, 1 to 77 months). The overall median age was 69 years (range 16-96). The crude mean annual incidence rate was 0, 38 per 100,000 inhabitants aged ≥15 years old and it was 0, 17/100,000 in men and 0, 21/100,000 in women. Overall survival was 39 months. According to the IPSS score, the high-risk forms are low and their overall survival was 15 months. The rate of transformation into acute myeloid leukaemia (AML) is 32%. Conclusion: This national epidemiological survey shows an annual progression rate of 19% and an increase in incidence from 0.007/100.000 in 2005 to 0.45/100.000 in 2019.
Keywords
